<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268045</url>
  </required_header>
  <id_info>
    <org_study_id>RTXM83-AC-01-11</org_study_id>
    <nct_id>NCT02268045</nct_id>
  </id_info>
  <brief_title>Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma</brief_title>
  <official_title>A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>mAbxience S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pisa® Farmacéutica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratorios de Productos Éticos C.E.I.S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratorio Elea Phoenix S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tecnoquimicas S.A</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innogene Kalbiotech Pte. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Libbs Farmacêutica LTDA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Key Oncologics (Pty) Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanolek LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Actoverco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>mAbxience S.A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, randomized study comparing the efficacy,
      pharmacokinetics (PK)/pharmacodynamics (PD), safety and immunogenicity profile of RTXM83
      (rituximab biosimilar) vs reference rituximab (MabThera®), both with CHOP, as first-line
      treatment of Diffuse-Large-B-Cell-Lymphoma (DLBCL).

      Rituximab biosimilar and MabThera® were both administered intravenously on Day 1 of each
      3-week cycle with CHOP chemotherapy for six cycles. Two additional cycles of treatment were
      permitted at the Investigator's discretion. Patients were followed up for 9 months after last
      study dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of the investigation is to determine if the response rate obtained with
      RTXM83 combined with CHOP is non inferior to the response rate obtained with reference
      rituximab combined with CHOP.

      The present study is a non inferiority trial and the study hypothesis is the following: H0:
      pc ≥ pe + δ vs. H1: pc &lt; pe + δ where, pe: proportion of successes in the experimental group
      (RTXM83+CHOP) pc: proportion of successes in the control group (Reference Rituximab+CHOP)
      Type I error: the difference pc-pe is less than δ when in fact the difference is greater than
      or equal to δ ie, the investigators choose the experimental treatment when the control
      treatment is actually substantially better.

      Type II error: the difference -pe is greater than or equal to δ when it is actually lest than
      δ ie, the investigators choose the control treatment when the experimental treatment is
      essentially just as good.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (RR) Achieved After Cycle 6 With RTXM83 Plus CHOP Compared to the RR Obtained With Mabthera® Plus CHOP (R-CHOP) in Patients With DLBCL</measure>
    <time_frame>Tumor response assessed after Cycle 6 or at the end of treatment</time_frame>
    <description>Per International Working Group (IWG) revised criteria for Malignant Lymphomas (Cheson et al. 2007) and assessed by positron-emission tomography scan, or by computed tomography scan and/or magnetic resonance imaging if Positron Emission Tomography (PET) scan was not feasible. Tumor response was classified according to the International Working Group criteria, as Complete Remission (CR): Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; Partial Response (PR): At least a 50% decrease in sum of the product of the diameters of up to six of the largest dominant nodes or nodal masses; Stable disease (SD) or; Progressive disease. Response rate was the sum of CR and PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC 0-∞ (h μg/mL) at Cycle 1 of RTXM83 and Mabthera®</measure>
    <time_frame>Cycle 1 (first dose): Day 1 (pre-dose, mid-infusion), Day 8 and Day 15</time_frame>
    <description>Compare the pharmacokinetic (PK) parameter (AUC 0-∞) calculated from start of the first infusion until start of the second infusion (i.e. at Cycle 1) in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (AUC 0-∞ ) falls completely within the range 80%-125%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-∞ (h μg/mL) at Cycle 6 of RTXM83 and Mabthera®</measure>
    <time_frame>Cycle 6 (last dose): Day 1, Day 8, Day 15 and Day 21</time_frame>
    <description>Compare the PK parameter (AUC 0-∞) calculated from start of the first infusion until Day 21 of administration of Cycle 6 in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (AUC 0-∞ ) falls completely within the range 80%-125%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (μg/mL) at Cycle 1 of RTXM83 and Mabthera®</measure>
    <time_frame>Cycle 1 (first dose): Day 1 (pre-dose, mid-infusion), Day 8 and Day 15</time_frame>
    <description>Compare the PK parameter (Cmax) calculated from start of the first infusion until start of the second infusion (i.e. at Cycle 1) in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (Cmax) falls completely within the range 80%-125%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (μg/mL) at Cycle 6 of RTXM83 and Mabthera®</measure>
    <time_frame>Cycle 6 (last dose): Day 1, Day 8, Day 15 and Day 21</time_frame>
    <description>Compare the PK parameter (Cmax) calculated from start of the first infusion until Day 21 of administration of Cycle 6 in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (AUC 0-∞ ) falls completely within the range 80%-125%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Pharmacodynamic (PD) Markers (CD19+ and CD20+ Cells) Blood Counts of RTXM83 and Mabthera®</measure>
    <time_frame>Up to follow-up 3 (FU3); 9 months after last dose of treatment</time_frame>
    <description>CD19 and CD20 are proteins found on the cell surface of B cells, and they can be detected in peripheral blood by flow cytometry. Flow cytometry of peripheral blood was performed for immediate analysis of cells with cluster of differentiation 19 (CD19+) and CD20+.
To compare the percent Change From Baseline ((Cycle 1 pre-dose) in pharmacodynamic markers (CD19+ and CD20+ Cells) in Peripheral Blood achieved in RTXM83 and Mabthera® arms at Cycle 1 end of infusion (EOI), 6 months and 9 months after last dose of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparable Safety Profile in Both Treatment Arms</measure>
    <time_frame>Up to FU3; 9 months after last dose of treatment</time_frame>
    <description>Compare the frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) reported in each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparable Immunogenicity Profile Between RTXM83 and Mabthera®</measure>
    <time_frame>Up to FU3; 9 months after last dose of treatment</time_frame>
    <description>Anti-Drug Antibody (ADA) developed de novo (seroconversion) after 6 cycles of treatment and 9 months of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS) in RTXM83 Arm and Mabthera® Arm</measure>
    <time_frame>Up to FU3; 9 months after last dose of treatment</time_frame>
    <description>Time from randomization to any of the following events: progressive disease, no achievement of CR, PR associated with treatment in excess of that per protocol, SD, relapse after achievement of CR, or death from any cause, whichever comes first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>RTXM83</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Ingredient: Rituximab (Biosimilar)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MabThera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Ingredient: Rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RTXM83</intervention_name>
    <description>Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.</description>
    <arm_group_label>RTXM83</arm_group_label>
    <other_name>Rituximab Biosimilar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mabthera</intervention_name>
    <description>Mabthera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.</description>
    <arm_group_label>MabThera</arm_group_label>
    <other_name>Reference rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with measurable disease defined as existence of a unidimensional or
             bidimensional lesion greater than 2 cm in its longest diameter or malignant
             lymphocytosis greater than 5x109/L. Any other procedure for measurable disease in
             particular cases, may be allowed upon Sponsor approval

          2. Newly diagnosed patients with a confirmed pathologic diagnosis of Diffuse large B
             cell-non-Hodgkin's lymphoma (DLBCL) with untreated CD20+ receptor (CD20+). Defined by
             the local Haematopathologist at the local laboratory according to World Health
             Organization (WHO) criteria

          3. Stage II-III or IV or stage I with bulk defined by the referring physician on the
             basis of the Cotswolds modification of the Ann Arbor classification 2

          4. Age-adjusted International Prognostic Index (IPI) score 0 or 1

          5. Age ≥18 to ≤65 years of age

          6. Performance status according to Eastern Cooperative Oncology Group (ECOG) of ≤2

          7. Written informed consent obtained before starting any study-specific procedure

          8. Females of child-bearing potential must test negative on standard serum pregnancy test
             and must be willing to practice appropriate contraceptive methods for the duration of
             the study (e.g. oral contraceptive, double barrier method, intra-uterine device,
             intra-muscular contraceptive)

          9. All male patients must take adequate contraceptive precautions during the course of
             the study

        Exclusion Criteria:

          1. Life expectancy of less than three months

          2. Any other lymphoma other than CD20+ DLBCL

          3. Indolent lymphoma, Primary central nervous system (CNS) Lymphoma or gastro-intestinal
             Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

          4. Known hypersensitivity to active ingredients, excipients and murine and foreign
             proteins

          5. Concurrent disease or general status that would exclude giving the treatment as
             outlined in the protocol

          6. Active uncontrolled infection requiring systemic treatment with antibiotics or
             antiviral agents at Screening or history of documented recurrent clinically
             significant infection (e.g. 2 or more viral, bacterial or fungal infections requiring
             inpatient treatment)

          7. Cardiac contra-indication to Doxorubicin therapy: non-compensated heart failure,
             dilated cardiomyopathy, coronary heart disease with ST segment depression on
             electrocardiogram (ECG), myocardial infarction in the last 6 months

          8. Neurologic contra-indication to Vincristine as it is indicated in the Summary of
             Product Characteristics (SmPC): (e.g. peripheral neuropathy)

          9. Chronic lung disease with hypoxemia measured by pulse oximetry (gasometry is not
             mandatory)

         10. Severe uncontrolled hypertension, despite optimal medical treatment

         11. Severe uncontrolled diabetes mellitus, despite optimal medical treatment

         12. Renal insufficiency (Serum Creatinine &gt;2 x Upper Normal Limit [UNL])

         13. Hepatic insufficiency: aspartate aminotransferase (AST)/ alanine aminotransferase
             (ALT)&gt;3 x UNL or &gt;5 x UNL with involvement of the liver, total bilirubin &gt;34.2 µmol/L,
             or both) not related to lymphoma

         14. Clinical signs of cerebral dysfunction

         15. Severe psychiatric disease

         16. Known human immunodeficiency virus (HIV) infection or active chronic hepatitis B or C

         17. Abnormal bone marrow function (platelets &lt;100x109/L, neutrophils &lt;1.5x109/L and
             Haemoglobin &lt;9g/dL)

         18. Post-transplantation lymphoproliferative disease

         19. Pregnant or lactating women or women that intend to get pregnant during study or
             within 12 months following the last infusion

         20. Treatment with any investigational product in the 30 days period before inclusion in
             the study

         21. Prior radiotherapy to treat the DLBCL Non-Hodgkin's Lymphoma (NHL)

         22. Limitation of the patient's ability to comply with the treatment or follow-up protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susana Millán, Phd</last_name>
    <role>Study Director</role>
    <affiliation>mAbxience S.A</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hosp. Interzonal &quot;R&quot; Carrillo</name>
      <address>
        <city>Ciudadela</city>
        <state>Bariloche</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Radiologica del Sur</name>
      <address>
        <city>Cipolletti</city>
        <state>Río Negro</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Viedma</name>
      <address>
        <city>Viedma</city>
        <state>Río Negro</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gral. de Agudos Donación Francisco Santojanni</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Roffo</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral (CORI)</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional de Clinicas</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr. Oncologico de Rosario</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. Cardiovascular Rosario</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Hematología y Medicina Clínica Dr. Rubén Dávoli</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación ARS Médica</name>
      <address>
        <city>San Salvador de Jujuy</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital J. B. Iturraspe</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Angel Padilla</name>
      <address>
        <city>Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinicas Porto Alegre</name>
      <address>
        <city>Pôrto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Caridade de Ijuí</name>
      <address>
        <city>Ijuí</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Cidade de Passo Fundo</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina</name>
      <address>
        <city>Itaquera</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Amaral Carvalho Jaú</name>
      <address>
        <city>Jaú</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo-HCFMRP</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia / Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Antônio Prudente - AC Camargo Câncer Center</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas-UFMG</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNICAMP-Univ Zeferino Vaz</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Uniao Oeste Paranaense de Estudos e Comabte ao Cancer (UOPECCAN)</name>
      <address>
        <city>Cascavel</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Erasto Gaertner CEPEP</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Universidade Federal de Goiás</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Clemente Fraga Filho - UFRJ</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto COI de Educação e Pesquisa</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Est. de Hematologia Arthur de Siqueira Cavalcanti</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monte Tabor - Hospital São Rafael</name>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa do Instituto Brasileiro de Controle do Câncer - IBCC</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinica Faculdade Medicina USP</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de São José</name>
      <address>
        <city>São José do Rio Prêto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. Nacional de Cancerologia</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Valle de Lili</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinivasam Cancer Care Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Institute and Research Centre</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bibi General Hospital&amp;Canc Ct</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birla Cancer Center - SMS Hospital</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Point Multi-specialty Hospital</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Transfusion Medicine</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netaji Subhash Chandra Bose Cancer Research Institute</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acharya Tulsi Regional Cancer Treatment and Research Institute</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guru Hospital</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meenakshi Mission Hospital</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kailash Cancer Hospital and Research Centre</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Hasan Sadikin Hospital</name>
      <address>
        <city>Bandung</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dharmais N. C. Center</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imam Khomeini Complex Hospital - Cancer Institute</name>
      <address>
        <city>Tehrān</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Aminah</name>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre - UMMC</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Miriam Cancer Hospital</name>
      <address>
        <city>Pulau Pinang</city>
        <zip>11200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>Pulau Pinang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insituto Nacional de Cancerología</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Privado de Hematologia e Investigaciona Clinica</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cebu Doctors University Hospital</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perpetual Succour Hospital</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davao Doctors Hospital</name>
      <address>
        <city>Davao</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Kidney and Transplant Institute</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Memorial Medical Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Clinical Oncology Dispensary</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kursk regional clinical oncology dispensary</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.N. Blokhin Russian Cancer Research Cente</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Surgical Center n.a. N.I. Pirogov</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murmansk regional oncology dispensary</name>
      <address>
        <city>Murmansk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Stavropol region &quot;Pyatigorsk oncology center&quot;</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov Scientific Research Oncology Institute</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Research Center for Radiology and Surgical Technologies</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budgetary Institution &quot;City Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Oncology n.a. N.N. Petrov</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Center # 2</name>
      <address>
        <city>Sochi</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komi Republican Oncology Dispensary</name>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Tula region &quot;Tula regional clinical hospital&quot;</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Clinical Oncology Center</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Oncology Centre</name>
      <address>
        <city>Amanzimtoti</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tygerberg Academic Hosp</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GVI Oncology</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Iran, Islamic Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Paraguay</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 19, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <results_first_submitted>March 11, 2019</results_first_submitted>
  <results_first_submitted_qc>August 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 26, 2019</results_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Diffuse large b-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>An additional cohort of 16 patients was added (as per Iran local regulatory requirements) to the planned sample of 256 patients. The extension cohort of Iran was only considered for safety analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RTXM83</title>
          <description>Rituximab biosimilar (RTXM83) was administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles. Administration of 2 additional cycles was allowed as per Investigator's criteria.</description>
        </group>
        <group group_id="P2">
          <title>MabThera</title>
          <description>MabThera was administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles. Administration of 2 additional cycles was allowed as per Investigator's criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RTXM83-CHOP</title>
          <description>Patients treated with Rituximab biosimilar in combination with CHOP chemotherapy</description>
        </group>
        <group group_id="B2">
          <title>MabThera-CHOP</title>
          <description>Patients treated with Rituximab in combination with CHOP chemotherapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="136"/>
            <count group_id="B3" value="272"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" lower_limit="40.0" upper_limit="57.0"/>
                    <measurement group_id="B2" value="51.0" lower_limit="41.0" upper_limit="59.0"/>
                    <measurement group_id="B3" value="51.0" lower_limit="40.0" upper_limit="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial disease stage (Ann Arbor Staging)</title>
          <description>The stage depends on both the place where the malignant tissue is located and on systemic symptoms due to the lymphoma. Ann Arbor Stage=I: Best condition; Ann Arbor Stage=IV: Worst condition
Stage I: cancer located in a single region; Stage II: cancer located in 2 separate regions that are confined to one side of the diaphragm; Stage III: cancer spreading to both sides of the diaphragm; Stage IV: diffuse or disseminated involvement of one or more extralymphatic organs.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stage I (with bulky)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stage IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of extra nodal lesions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Performance Status according to Eastern Cooperative Oncology Group (ECOG)</title>
          <description>Measure Description: ECOG=0: Fully active, able to carry on all pre-disease performance without restriction; ECOG =1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing data</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age-adjusted International Prognostic Index (IPI)</title>
          <description>Age-adjusted IPI is a simplified index for comparing patients within an age group (i.e. 60 or younger, or over 60) and includes the evaluation of 3 clinical factors: Ann Arbor stage III or IV disease; ECOG performance status &gt;=2 and ; increased serum lactate dehydrogenase levels.
The sum of the points allotted correlates with the following risk groups:
Low risk (0 points) - 5-year survival of 83%; Low-intermediate risk (1 point) - 5-year survival of 69%; High-intermediate risk (2 points) - 5-year survival of 46%; High risk (3 points) - 5-year survival of 32%.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (RR) Achieved After Cycle 6 With RTXM83 Plus CHOP Compared to the RR Obtained With Mabthera® Plus CHOP (R-CHOP) in Patients With DLBCL</title>
        <description>Per International Working Group (IWG) revised criteria for Malignant Lymphomas (Cheson et al. 2007) and assessed by positron-emission tomography scan, or by computed tomography scan and/or magnetic resonance imaging if Positron Emission Tomography (PET) scan was not feasible. Tumor response was classified according to the International Working Group criteria, as Complete Remission (CR): Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; Partial Response (PR): At least a 50% decrease in sum of the product of the diameters of up to six of the largest dominant nodes or nodal masses; Stable disease (SD) or; Progressive disease. Response rate was the sum of CR and PR.</description>
        <time_frame>Tumor response assessed after Cycle 6 or at the end of treatment</time_frame>
        <population>The Intent-to-treat (ITT) population and the Per Protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>RTXM83-CHOP</title>
            <description>Patients treated with Rituximab biosimilar in combination with CHOP chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>MabThera-CHOP</title>
            <description>Patients treated with Rituximab in combination with CHOP chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (RR) Achieved After Cycle 6 With RTXM83 Plus CHOP Compared to the RR Obtained With Mabthera® Plus CHOP (R-CHOP) in Patients With DLBCL</title>
          <description>Per International Working Group (IWG) revised criteria for Malignant Lymphomas (Cheson et al. 2007) and assessed by positron-emission tomography scan, or by computed tomography scan and/or magnetic resonance imaging if Positron Emission Tomography (PET) scan was not feasible. Tumor response was classified according to the International Working Group criteria, as Complete Remission (CR): Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; Partial Response (PR): At least a 50% decrease in sum of the product of the diameters of up to six of the largest dominant nodes or nodal masses; Stable disease (SD) or; Progressive disease. Response rate was the sum of CR and PR.</description>
          <population>The Intent-to-treat (ITT) population and the Per Protocol (PP) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ITT : Response rate (CR+PR)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="75.8" upper_limit="89.7"/>
                    <measurement group_id="O2" value="82.9" lower_limit="74.8" upper_limit="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PP : Response rate (CR+PR)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" lower_limit="76.6" upper_limit="90.8"/>
                    <measurement group_id="O2" value="81.7" lower_limit="72.9" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>The RR, with the corresponding 95% CI, was calculated for each treatment arm and compared using Fisher's exact test at a one-sided 0.025 type I error rate. A non-inferiority margin of 13% was assumed with ≥ 80% power to detect treatment differences. Non-inferiority was concluded if the one-sided 95% CI was above the -13% margin set for the study.</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-13</ci_lower_limit>
            <estimate_desc>For the ITT population</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>The RR, with the corresponding 95% CI, was calculated for each treatment arm and compared using Fisher's exact test at a one-sided 0.025 type I error rate. A non-inferiority margin of 13% was assumed with ≥ 80% power to detect treatment differences. Non-inferiority was concluded if the one-sided 95% CI was above the -13% margin set for the study.</non_inferiority_desc>
            <param_type>percentage difference</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-13</ci_lower_limit>
            <estimate_desc>For the PP population</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-∞ (h μg/mL) at Cycle 1 of RTXM83 and Mabthera®</title>
        <description>Compare the pharmacokinetic (PK) parameter (AUC 0-∞) calculated from start of the first infusion until start of the second infusion (i.e. at Cycle 1) in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (AUC 0-∞ ) falls completely within the range 80%-125%.</description>
        <time_frame>Cycle 1 (first dose): Day 1 (pre-dose, mid-infusion), Day 8 and Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RTXM83-CHOP</title>
            <description>Patients treated with Rituximab biosimilar with CHOP chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>MabThera- CHOP</title>
            <description>Patients treated with Rituximab in combination with CHOP chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-∞ (h μg/mL) at Cycle 1 of RTXM83 and Mabthera®</title>
          <description>Compare the pharmacokinetic (PK) parameter (AUC 0-∞) calculated from start of the first infusion until start of the second infusion (i.e. at Cycle 1) in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (AUC 0-∞ ) falls completely within the range 80%-125%.</description>
          <units>ng.h/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44519" spread="32"/>
                    <measurement group_id="O2" value="44874" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80%–125%.</non_inferiority_desc>
            <param_type>ratio RTXM83 to Mabthera</param_type>
            <param_value>99.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.6</ci_lower_limit>
            <ci_upper_limit>105</ci_upper_limit>
            <estimate_desc>For the ratio: RTXM83 represents the numerator and Mabthera the denominator</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC 0-∞ (h μg/mL) at Cycle 6 of RTXM83 and Mabthera®</title>
        <description>Compare the PK parameter (AUC 0-∞) calculated from start of the first infusion until Day 21 of administration of Cycle 6 in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (AUC 0-∞ ) falls completely within the range 80%-125%.</description>
        <time_frame>Cycle 6 (last dose): Day 1, Day 8, Day 15 and Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RTXM83-CHOP</title>
            <description>Patients treated with Rituximab biosimilar with CHOP chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>MabThera- CHOP</title>
            <description>Patients treated with Rituximab in combination with CHOP chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-∞ (h μg/mL) at Cycle 6 of RTXM83 and Mabthera®</title>
          <description>Compare the PK parameter (AUC 0-∞) calculated from start of the first infusion until Day 21 of administration of Cycle 6 in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (AUC 0-∞ ) falls completely within the range 80%-125%.</description>
          <units>ng.h/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60875" spread="22"/>
                    <measurement group_id="O2" value="59079" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80%–125%.</non_inferiority_desc>
            <param_type>ratio RTXM83 to Mabthera</param_type>
            <param_value>103</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.5</ci_lower_limit>
            <ci_upper_limit>107</ci_upper_limit>
            <estimate_desc>For the ratio: RTXM83 represents the numerator and Mabthera the denominator</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (μg/mL) at Cycle 1 of RTXM83 and Mabthera®</title>
        <description>Compare the PK parameter (Cmax) calculated from start of the first infusion until start of the second infusion (i.e. at Cycle 1) in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (Cmax) falls completely within the range 80%-125%.</description>
        <time_frame>Cycle 1 (first dose): Day 1 (pre-dose, mid-infusion), Day 8 and Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RTXM83-CHOP</title>
            <description>Patients treated with Rituximab biosimilar with CHOP chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>MabThera- CHOP</title>
            <description>Patients treated with Rituximab in combination with CHOP chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (μg/mL) at Cycle 1 of RTXM83 and Mabthera®</title>
          <description>Compare the PK parameter (Cmax) calculated from start of the first infusion until start of the second infusion (i.e. at Cycle 1) in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (Cmax) falls completely within the range 80%-125%.</description>
          <units>μg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.8" spread="24"/>
                    <measurement group_id="O2" value="197.5" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80%–125%.</non_inferiority_desc>
            <param_type>ratio RTXM83 to Mabthera</param_type>
            <param_value>99.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.9</ci_lower_limit>
            <ci_upper_limit>105</ci_upper_limit>
            <estimate_desc>For the ratio: RTXM83 represents the numerator and Mabthera the denominator</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (μg/mL) at Cycle 6 of RTXM83 and Mabthera®</title>
        <description>Compare the PK parameter (Cmax) calculated from start of the first infusion until Day 21 of administration of Cycle 6 in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (AUC 0-∞ ) falls completely within the range 80%-125%.</description>
        <time_frame>Cycle 6 (last dose): Day 1, Day 8, Day 15 and Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RTXM83-CHOP</title>
            <description>Patients treated with Rituximab biosimilar with CHOP chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>MabThera- CHOP</title>
            <description>Patients treated with Rituximab in combination with CHOP chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (μg/mL) at Cycle 6 of RTXM83 and Mabthera®</title>
          <description>Compare the PK parameter (Cmax) calculated from start of the first infusion until Day 21 of administration of Cycle 6 in a population PK model.
For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio between the geometric means of the measure (AUC 0-∞ ) falls completely within the range 80%-125%.</description>
          <units>μg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291" spread="21"/>
                    <measurement group_id="O2" value="279" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80%–125%.</non_inferiority_desc>
            <param_type>ratio RTXM83 to Mabthera</param_type>
            <param_value>104</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.5</ci_lower_limit>
            <ci_upper_limit>109</ci_upper_limit>
            <estimate_desc>For the ratio: RTXM83 represents the numerator and Mabthera the denominator</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Pharmacodynamic (PD) Markers (CD19+ and CD20+ Cells) Blood Counts of RTXM83 and Mabthera®</title>
        <description>CD19 and CD20 are proteins found on the cell surface of B cells, and they can be detected in peripheral blood by flow cytometry. Flow cytometry of peripheral blood was performed for immediate analysis of cells with cluster of differentiation 19 (CD19+) and CD20+.
To compare the percent Change From Baseline ((Cycle 1 pre-dose) in pharmacodynamic markers (CD19+ and CD20+ Cells) in Peripheral Blood achieved in RTXM83 and Mabthera® arms at Cycle 1 end of infusion (EOI), 6 months and 9 months after last dose of treatment.</description>
        <time_frame>Up to follow-up 3 (FU3); 9 months after last dose of treatment</time_frame>
        <population>Data were provided for the number of samples available at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>RTXM83-CHOP</title>
            <description>Patients treated with Rituximab biosimilar with CHOP chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>MabThera- CHOP</title>
            <description>Patients treated with Rituximab in combination with CHOP chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Pharmacodynamic (PD) Markers (CD19+ and CD20+ Cells) Blood Counts of RTXM83 and Mabthera®</title>
          <description>CD19 and CD20 are proteins found on the cell surface of B cells, and they can be detected in peripheral blood by flow cytometry. Flow cytometry of peripheral blood was performed for immediate analysis of cells with cluster of differentiation 19 (CD19+) and CD20+.
To compare the percent Change From Baseline ((Cycle 1 pre-dose) in pharmacodynamic markers (CD19+ and CD20+ Cells) in Peripheral Blood achieved in RTXM83 and Mabthera® arms at Cycle 1 end of infusion (EOI), 6 months and 9 months after last dose of treatment.</description>
          <population>Data were provided for the number of samples available at each visit.</population>
          <units>percentage change in cells</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 EOI, CD19+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-96.8" lower_limit="-100" upper_limit="10"/>
                    <measurement group_id="O2" value="-94.6" lower_limit="-100" upper_limit="525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months after last dose, CD19+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-95.7" lower_limit="-100" upper_limit="833"/>
                    <measurement group_id="O2" value="-98.3" lower_limit="-100" upper_limit="4380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 9 months after last dose, CD19+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33" lower_limit="-100" upper_limit="13600"/>
                    <measurement group_id="O2" value="-42.3" lower_limit="-100" upper_limit="10300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 EOI, CD20+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-100" lower_limit="-100" upper_limit="-16.7"/>
                    <measurement group_id="O2" value="-100" lower_limit="-100" upper_limit="7400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 months after last dose, CD20+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-98.9" lower_limit="-100" upper_limit="700"/>
                    <measurement group_id="O2" value="-100" lower_limit="-100" upper_limit="6990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 9 months after last dose, CD20+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.2" lower_limit="-100" upper_limit="69100"/>
                    <measurement group_id="O2" value="-30.6" lower_limit="-100" upper_limit="12400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparable Safety Profile in Both Treatment Arms</title>
        <description>Compare the frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) reported in each treatment arm.</description>
        <time_frame>Up to FU3; 9 months after last dose of treatment</time_frame>
        <population>All patients receiving at least one dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>RTXM83-CHOP</title>
            <description>Patients treated with Rituximab biosimilar in combination with CHOP chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>MabThera-CHOP</title>
            <description>Patients treated with Rituximab in combination with CHOP chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Comparable Safety Profile in Both Treatment Arms</title>
          <description>Compare the frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) reported in each treatment arm.</description>
          <population>All patients receiving at least one dose of the study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one TEAE (any causality)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one grade 3/4 TEAE (any causality)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs related to treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs (any causality)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE led to drug discontinuation (any causality)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparable Immunogenicity Profile Between RTXM83 and Mabthera®</title>
        <description>Anti-Drug Antibody (ADA) developed de novo (seroconversion) after 6 cycles of treatment and 9 months of follow-up.</description>
        <time_frame>Up to FU3; 9 months after last dose of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RTXM83-CHOP</title>
            <description>Patients treated with Rituximab biosimilar in combination with CHOP chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>MabThera-CHOP</title>
            <description>Patients treated with Rituximab in combination with CHOP chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Comparable Immunogenicity Profile Between RTXM83 and Mabthera®</title>
          <description>Anti-Drug Antibody (ADA) developed de novo (seroconversion) after 6 cycles of treatment and 9 months of follow-up.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No seroconversion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Free Survival (EFS) in RTXM83 Arm and Mabthera® Arm</title>
        <description>Time from randomization to any of the following events: progressive disease, no achievement of CR, PR associated with treatment in excess of that per protocol, SD, relapse after achievement of CR, or death from any cause, whichever comes first.</description>
        <time_frame>Up to FU3; 9 months after last dose of treatment</time_frame>
        <population>Number of patients with an EFS event (progressive disease, no achievement of CR, PR associated with treatment more than that per protocol, stable disease, relapse after achievement of CR, or death from any cause, whichever comes first).</population>
        <group_list>
          <group group_id="O1">
            <title>RTXM83-CHOP</title>
            <description>Patients treated with Rituximab biosimilar with CHOP chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>MabThera- CHOP</title>
            <description>Patients treated with Rituximab in combination with CHOP chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Event Free Survival (EFS) in RTXM83 Arm and Mabthera® Arm</title>
          <description>Time from randomization to any of the following events: progressive disease, no achievement of CR, PR associated with treatment in excess of that per protocol, SD, relapse after achievement of CR, or death from any cause, whichever comes first.</description>
          <population>Number of patients with an EFS event (progressive disease, no achievement of CR, PR associated with treatment more than that per protocol, stable disease, relapse after achievement of CR, or death from any cause, whichever comes first).</population>
          <units>time (months)</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="4.4" upper_limit="NA">Upper limit of the Confidence Interval was not achieved due to short time follow up</measurement>
                    <measurement group_id="O2" value="8.6" lower_limit="4.6" upper_limit="NA">Upper limit of the Confidence Interval was not achieved due to short time follow up</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4570</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the study start, during the study and up to 30 days after the end of study treatment.</time_frame>
      <desc>Graded according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC; version 4.0) and categorized using the MedDRA (version 16.0) terminology.</desc>
      <group_list>
        <group group_id="E1">
          <title>RTXM83-CHOP</title>
          <description>Patients treated with Rituximab biosimilar in combination with CHOP chemotherapy</description>
        </group>
        <group group_id="E2">
          <title>MabThera-CHOP</title>
          <description>Patients treated with Rituximab in combination with CHOP chemotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susana Millan</name_or_title>
      <organization>mAbxience</organization>
      <phone>+34917711500 ext 9284</phone>
      <email>Susana.Millan@mabxience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

